US 11,866,504 B2
Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof
Michael Kershaw, Ocean Gove (AU); Clare Slaney, Greensborough (AU); and Bianca Von Scheidt, Ascot Vale (AU)
Assigned to Peter MacCallum Cancer Institute, Melbourne (AU)
Appl. No. 17/289,997
Filed by Peter MacCallum Cancer Institute, Melbourne (AU)
PCT Filed Oct. 29, 2019, PCT No. PCT/AU2019/051189
§ 371(c)(1), (2) Date Apr. 29, 2021,
PCT Pub. No. WO2020/087116, PCT Pub. Date May 7, 2020.
Claims priority of application No. 2018904117 (AU), filed on Oct. 30, 2018; and application No. 2019903255 (AU), filed on Sep. 4, 2019.
Prior Publication US 2022/0017628 A1, Jan. 20, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); C07K 16/24 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 35/17 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/247 (2013.01); C07K 16/2809 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/33 (2013.01)] 16 Claims
 
1. A method of treating a solid tumor in a subject, the method comprising:
administering to a subject in need thereof:
(i) an immune cell expressing a chimeric antigen receptor (CAR) that binds to an antigen on the tumor; and
(ii) a bispecific polypeptide comprising a 1st binding domain and a 2nd binding domain, wherein the 1st binding domain specifically binds to an antigen expressed on an endogenous professional antigen presenting cell (APC) of the subject, wherein the endogenous professional APC is not a tumor cell; and wherein the 2nd binding domain specifically binds to an affinity tag on the CAR of the immune cell,
thereby treating the solid tumor in the subject,
wherein the antigen expressed on said endogenous professional antigen presenting cell is:
(i) not an antigen on the tumor;
(ii) not an antigen that is a tumor-associated antigen on the tumor; or
(iii) not differentially expressed by the tumor compared to a non-tumor cell of the same tissue type.